RxDoctor Payments Data

Sarah Trampota, MD

Interventional Pain Medicine · San Antonio, TXNPI 1043491970

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $25,217 of the $36,816 with a category attached, or 68.5%. 31 manufacturers reported payments, led by Nevro Corp. at 31.4% of the total. Reporting peaked in 2019 at $14,058 and has fallen 59.5% since, to $5,698 in 2025.

$36,816in general payments, 2019–2025

Across 600 payments — averaging $61.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$12K
  • Boston Scientific$6K
  • SPR Therapeutics, Inc$6K
  • Saluda Medical Americas, Inc.$4K
  • Abbott$3K
  • Globus Medical$1K
  • plus $5K from 25 others
$16in research payments, 2019–2025

Across 1 payment — averaging $16.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Saluda Medical Americas, Inc.$16

What the payments were for

  • Consulting fees$3,60010%
  • Travel & lodging$7,99922%
  • Food & beverage$25,21768%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,816 in reported general payments places this provider in the 85th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$303,999
Medicare patients
162
Services billed
14,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen571$17,712
Lubiprostone81$6,001
Gabapentin383$5,625
Tramadol Hcl361$3,280
Pregabalin127$2,326
Lidocaine21$1,812
Ibuprofen127$1,555
Diclofenac Sodium26$1,488
Fentanyl11$1,036
Celecoxib49$1,006
Tizanidine Hcl85$659
Methadone Hcl21$640
Nortriptyline Hcl35$393
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$375
Acetaminophen-CodeineAcetaminophen With Codeine20$330

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →